A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants

NCT05469113 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Repaglinide
DRUG: Selpercatinib

Sponsor

Eli Lilly and Company

Collaborators

[object Object]